Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Atmungsmechanik zur Abgabe individualisierter exogener Tenside (REMEDIES)

2. November 2026 aktualisiert von: Anna Lavizzari, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

Eine randomisierte kontrollierte Studie zur Oszillationsmechanik im Vergleich zu sauerstoffbasierten Kriterien für die Surfactant-Therapie

This study is an interventional, non-pharmacological, multicentric, randomized, controlled, superiority, non-profit study. Its primary objective is to evaluate if the administration of surfactant based on FOT assessment will allow a 5-day reduction in the duration of respiratory support as compared to standard practice in preterm infants between 27+0 and 32+6 weeks' gestation. The secondary objectives are:

  1. to determine if a lung mechanics-based approach for administering surfactant will change treatment timing; and
  2. to assess the impact of the novel approach on other neonatal general outcomes. The study will take place within the neonatal intensive care units. Non-invasive respiratory support will be delivered by nasal CPAP with a starting pressure of 5-8 cmH2O. FiO2 will be titrated in order to achieve the target SpO2 91-95%.

Infants matching the clinical criteria for inclusion will be randomized in two arms following the current data protection and confidentiality regulations. Central, computer-generated randomization (allocation 1:1) with variable block sizes according to gestational age will be used. Infants will be stratified according to gestational age (27+0 -28+6 weeks; 29+0 -30+6 weeks; 31+0 -32+6 weeks) and center.

Study Arms:

A) Surfactant administration following oxygenation-based criteria (clinical assessment) (control) B) Surfactant administration following both lung mechanics assessment OR oxygenation-based criteria (clinical assessment) (intervention).

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

458

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Milan, Italien
        • Rekrutierung
        • Fondazione IRCCs Cà Granda Ospedale Maggiore Policlinico
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

6 Monate bis 7 Monate (Kind)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Gestational age (GA) ≥ 27+0 and < 33+0 weeks
  2. Spontaneously breathing infants, requiring non-invasive respiratory support (nasal CPAP or bilevel nasal CPAP). Criteria for commencement of non-invasive respiratory support: FiO2 >0.30 for target SpO2 88-93% or Silverman score ≥ 5.
  3. Inborn
  4. Written parental consent obtained
  5. Administration of Caffeine bolus 20 mg/kg IV or PO as per standard care

Exclusion Criteria:

  1. Major congenital anomalies
  2. Need of intubation in delivery suite according to the AAP guidelines for neonatal resuscitation or early at the admission in NICU (within one hour from birth).
  3. Surfactant therapy prior to the study entry
  4. Severe birth asphyxia, defined by APGAR score ≤ 5 at 10 minutes after birth OR continued need for resuscitation 10 minutes after birth OR pH < 7.0 or base excess (BE) < -12 mmol/l on umbilical cord or on an arterial or capillary blood sample obtained within 1 hour from birth OR moderate to severe encephalopathy
  5. Respiratory failure secondary to conditions other that RDS as identified by lung imaging (air leaks, lung malformations…)
  6. Any clinical condition which may place the infants at undue risk as deemed by clinicians
  7. Participation to trials with competitive outcomes or likely to have an impact on the primary outcome of the study
  8. Outborn patients

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Verdreifachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: A/Control

Surfactant administration following clinical assessment

Surfactant is administered following oxygenation-based criteria

Experimental: B/Intervention

Surfactant administration following both lung mechanics assessment and clinical assessment

Surfactant is administered following oxygenation-based criteria and if the Xrs is ≤ -23.3 cmH2O*s /L

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Days of respiratory support
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days of required respiratory support

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
First surfactant administration
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Time of first surfactant administration (in hours)

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Days of non-invasive respiratory support
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days of non-invasive respiratory support

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Days of invasive respiratory support
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days of invasive respiratory support

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Patients intubated and mechanically ventilated
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of patients intubated and mechanically ventilated

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Patients receiving multiple surfactant doses
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of patients receiving multiple surfactant doses

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Days on supplemental oxygen
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days on supplemental oxygen

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Total cumulative oxygen exposure
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Total cumulative oxygen exposure computed as the time integral of the FiO2 values

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants receiving more than 28 days of respiratory support
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants receiving more than 28 days of respiratory support

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants developing BPD
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants developing BPD according to the definition by NICHD 2016

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants developing air-leaks
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants developing air-leaks

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants developing prematurity-associated complications
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants developing prematurity-associated complications (severe intraventricular haemorrhage (IVH), periventricular leukomalacia (PVL), necrotizing enterocolitis (NEC), sepsis, retinopathy of prematurity (ROP), patent ductus arteriosus requiring pharmacological or surgical treatment)

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants discharged home with oxygen or respiratory support
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants discharged home with oxygen or respiratory support

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Days to achieve full-enteral feeding
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days to achieve full-enteral feeding (160 ml/kg/day of milk intake)

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Days of hospitalization
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of days of hospitalization

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"
Infants receiving postnatal steroids
Zeitfenster: From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Number of infants receiving postnatal steroids

From date of randomization until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 48 months"

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

15. Dezember 2023

Primärer Abschluss (Geschätzt)

30. Mai 2028

Studienabschluss (Geschätzt)

31. Dezember 2028

Studienanmeldedaten

Zuerst eingereicht

9. Dezember 2022

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

28. März 2023

Zuerst gepostet (Tatsächlich)

30. März 2023

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

5. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

2. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • Sperimentazione 3115
  • Studio Numero 6379 (Andere Kennung: Comitato Etico Milano Area 2)

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .